Venus Remedies Limited (VENUSREM) AI Stock Analysis

• Market Cap: ₹10.66B
• Dividend Yield: N/A
• Average Volume (3M): 2.33K
• Price to Earnings (P/E): 14.6
• Beta (1Y): 0.94
• Revenue Growth: 13.32%
• EPS Growth: 218.38%
• Country: IN
• Employees: 1,187
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 15.06
• Shares Outstanding: 13,366,988
• 10 Day Avg. Volume: 2,529
• 30 Day Avg. Volume: 2,330
• PEG Ratio: 0.16
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 0.65
• P/FCF Ratio: 5.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: ₹717.00 ▼(-12.89% Downside)

Venus Remedies Limited's strong financial performance is the primary driver of its score, supported by robust revenue growth and effective cash flow management. The technical analysis suggests strong momentum, though caution is advised due to overbought signals. The valuation is reasonable, but the lack of a dividend yield may deter some investors.

Positive Factors

Revenue Growth

Consistent revenue growth indicates expanding market presence and successful product adoption, supporting long-term business sustainability.

Cash Generation

Strong cash generation enhances financial flexibility, enabling reinvestment in growth opportunities and reducing reliance on external financing.

Profit Margins

Improved profit margins demonstrate effective cost management and operational efficiency, contributing to sustainable profitability.

Negative Factors

Dividend Policy

Lack of dividends may deter income-seeking investors, potentially limiting the shareholder base and affecting stock attractiveness.

Equity Base

While a strong equity base is positive, it may indicate under-leveraging, potentially limiting growth acceleration through strategic debt.

Market Volatility

High market volatility and overbought conditions may lead to price instability, impacting investor confidence and stock performance.

Venus Remedies Limited Business Overview & Revenue Model

Company Description

Venus Remedies Limited (VENUSREM) is a leading pharmaceutical company based in India, specializing in the development, manufacturing, and marketing of a diverse range of generic and innovative pharmaceutical products. The company operates in various sectors, including injectables, oral solids, and advanced drug delivery systems, with a strong focus on providing high-quality, cost-effective therapeutic solutions across multiple therapeutic areas such as oncology, cardiology, and infectious diseases. Venus Remedies is also engaged in contract manufacturing and has established a global presence through exports to numerous countries.

How the Company Makes Money

Venus Remedies generates revenue primarily through the sale of its pharmaceutical products, which include a wide array of generic drugs and proprietary formulations. Key revenue streams include domestic sales within India and international sales through exports to various markets, including Europe, the Middle East, and Africa. The company also earns income from contract manufacturing services, allowing it to leverage its production capabilities for third-party clients. Strategic partnerships with healthcare providers and distributors enhance its market reach and facilitate entry into new geographical markets. Additionally, research and development investments lead to the creation of innovative products, contributing to long-term revenue growth.

Venus Remedies Limited Financial Statement Overview

Summary

Venus Remedies Limited demonstrates a strong financial position with consistent revenue growth, robust profit margins, and effective cash flow management. The company exhibits financial stability with a low reliance on debt and a strong equity base, suggesting a solid financial foundation and potential for sustained growth.

Income Statement

Venus Remedies Limited has demonstrated strong revenue growth over the years, with a significant increase from 2020 to 2025. The company maintains a healthy Gross Profit Margin, indicating efficient production and cost management. The Net Profit Margin has improved significantly compared to earlier losses, reflecting enhanced operational efficiency and profitability. The EBIT and EBITDA margins are solid, showcasing robust earnings performance before interest, taxes, and non-cash expenses.

Balance Sheet

The company displays a strong equity position with a high Equity Ratio, suggesting financial stability and a low reliance on debt. The Debt-to-Equity Ratio is favorable, indicating low financial leverage and reduced risk of financial distress. Return on Equity has shown consistent improvement, reflecting effective use of shareholders' equity in generating profits.

Cash Flow

Venus Remedies Limited exhibits strong cash flow performance, with a significant positive Free Cash Flow trend, indicating good cash generation after capital expenditures. The Operating Cash Flow to Net Income Ratio is robust, highlighting efficient conversion of earnings into cash. There is a significant increase in Free Cash Flow over the years, underscoring the company's strong cash-generating capabilities.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.71B	6.48B	5.91B	5.56B	5.99B	5.48B
Gross Profit	2.22B	1.66B	2.18B	2.25B	2.00B	1.07B
EBITDA	1.00B	944.10M	711.80M	703.46M	701.40M	968.49M
Net Income	537.10M	453.20M	284.91M	265.70M	407.24M	617.65M
Balance Sheet
Total Assets	0.00	7.16B	6.27B	6.01B	5.80B	5.56B
Cash, Cash Equivalents and Short-Term Investments	1.56B	1.64B	838.05M	720.77M	432.56M	288.79M
Total Debt	0.00	16.90M	413.25M	422.90M	428.45M	513.18M
Total Liabilities	-5.61B	1.55B	1.39B	1.41B	1.39B	1.56B
Stockholders Equity	5.61B	5.61B	4.88B	4.60B	4.40B	4.00B
Cash Flow
Free Cash Flow	0.00	812.90M	278.40M	288.02M	272.94M	1.25B
Operating Cash Flow	0.00	909.20M	372.85M	366.20M	410.01M	1.33B
Investing Cash Flow	0.00	-807.90M	-72.09M	-508.30M	-166.26M	557.16M
Financing Cash Flow	0.00	-9.50M	-10.83M	-5.70M	-94.77M	-1.62B

Venus Remedies Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 823.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VENUSREM, the sentiment is Positive. The current price of 823.1 is above the 20-day moving average (MA) of 741.15, above the 50-day MA of 578.87, and above the 200-day MA of 448.37, indicating a bullish trend. The MACD of 65.58 indicates Positive momentum. The RSI at 67.72 is Neutral, neither overbought nor oversold. The STOCH value of 66.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VENUSREM.

Venus Remedies Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	72 Outperform	₹10.66B	14.61	―	―	13.32%	218.38%
INDSWFTLAB	70 Outperform	₹7.77B	2.65	―	―	-37.70%	-19.79%
MEDICAMEQ	65 Neutral	₹5.33B	47.90	―	0.25%	-9.16%	49.09%
ZIMLAB	63 Neutral	₹3.43B	52.95	―	―	-5.82%	-59.22%
KILITCH	57 Neutral	₹5.89B	19.80	―	―	32.95%	67.39%
NECLIFE	52 Neutral	₹4.75B	-1.31	―	―	-30.27%	-3470.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Venus Remedies Limited Corporate Events

Venus Remedies Ensures Compliance with SEBI Regulations

Venus Remedies Limited has announced compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The company has confirmed that securities received for dematerialization during the quarter ending September 30, 2025, were processed and listed on the stock exchanges. This compliance ensures that the securities are accurately reflected in the depositories’ records, maintaining transparency and trust with stakeholders.